MNPR
Monopar TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
ALXN1840 clinical data and a successful NDA submission could create a regulatory and commercial rerating, while the reported cash position provides meaningful development runway.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.0.
What can break
Commercial launch execution and demand remain unproven.
Momentum
99
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $115.00 · Bull $145.00 · Bear $75.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $114.75
Why
Momentum99 · Δ7d +1.0
Value41 · Δ7d +0.1
Sentiment46 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
+1.0
Δ21d
+10.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
46
34% active weight
Current posture
7d trendImproving
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 98.6 / Value 41.1 / Sentiment 46.3
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$760.81M
Beta
1.54
Shares Out
6.7M
P/E (TTM) · Derived
-61.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-83.63
Rev YoY
-
EPS YoY
+21.4%
Gross Margin
-
Op Margin
-
Net Debt
-$140.24M
Current Ratio
56.04
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology